Clinical TrialsClinical trials are scientific studies designed to evaluate the effectiveness and safety of a new drug by monitoring their effects. Qurient has been conducting clinical trials in various disease indications. Additional information about our clinical trials is available at www.clinicaltrials.gov, which is a resource provided by the U.S. National Library of Medicine. For more information, please contact Qurient Co., Ltd. (+82-31-8060-1600 or clinicaltrial_info@qurient.com).
| Pipeline | Condition/Disease | Phase | Link | Status | Result |
|---|---|---|---|---|---|
| Q901 |
Advanced Cancer Metastatic Cancer |
1/2 | NCT05394103 | Recruiting | |
| Adrixetinib, Q702 | Solid Tumors | 1 | NCT04648254 | Active, not recruiting | |
| Adrixetinib, Q702 | Acute Myeloid Leukemia | 1 | NCT06445907 | Not yet recruiting | |
| Adrixetinib, Q702 | Hematologic Malignancies | 1 | NCT06712810 | Not yet recruiting | |
| Adrixetinib, Q702 |
Esophageal Cancer Gastric Cancer Hepatocellular Cancer Cervical Cancer |
1B/2 | NCT05438420 | Recruiting | |
| Telacebec, Q203 |
Healthy volunteers |
1 | NCT02530710 | Completed | |
| Telacebec, Q203 | Healthy volunteers | 1 | NCT02858973 | Completed | |
| Telacebec, Q203 | Pulmonary Tuberculosis | 2 | NCT03563599 | Completed | Telacebec (Q203), a New Antituberculosis Agent. |
| Telacebec, Q203 | Buruli Ulcer | 2 | NCT06481163 | Active, not recruiting | |
| Q301 | Atopic Dermatitis | 2 | NCT02426359 | Completed | Poster: 2019 AAD annual meeting. |
| Q301 | Atopic Dermatitis | 2 | NCT03571620 | Completed |
| Pipeline | Q901 |
|---|---|
| Condition/Disease |
Advanced Cancer Metastatic Cancer |
| Phase | 1/2 |
| Link | NCT05394103 |
| Status | Recruiting |
| Result |
| Pipeline | Adrixetinib, Q702 |
|---|---|
| Condition/Disease | Solid Tumors |
| Phase | 1 |
| Link | NCT04648254 |
| Status | Active, not recruiting |
| Result |
| Pipeline | Adrixetinib, Q702 |
|---|---|
| Condition/Disease | Acute Myeloid Leukemia |
| Phase | 1 |
| Link | NCT06445907 |
| Status | Not yet recruiting |
| Result |
| Pipeline | Adrixetinib, Q702 |
|---|---|
| Condition/Disease | Hematologic Malignancies |
| Phase | 1 |
| Link | NCT06712810 |
| Status | Not yet recruiting |
| Result |
| Pipeline | Adrixetinib, Q702 |
|---|---|
| Condition/Disease |
Esophageal Cancer Gastric Cancer Hepatocellular Cancer Cervical Cancer |
| Phase | 1B/2 |
| Link | NCT05438420 |
| Status | Recruiting |
| Result |
| Pipeline | Adrixetinib, Q702 |
|---|---|
| Condition/Disease |
Esophageal Cancer Gastric Cancer Hepatocellular Cancer Cervical Cancer |
| Phase | 1B/2 |
| Link | NCT05438420 |
| Status | Active, not recruiting |
| Result |
| Pipline | Telacebec, Q203 |
|---|---|
| Condition/Disease | Healthy volunteers |
| Phase | 1 |
| Link | NCT02530710 |
| Status | Completed |
| Result |
| Pipline | Telacebec, Q203 |
|---|---|
| Condition/Disease | Healthy volunteers |
| Phase | 1 |
| Link | NCT02858973 |
| Status | Completed |
| Result |
| Pipline | Telacebec, Q203 |
|---|---|
| Condition/Disease | Pulmonary Tuberculosis |
| Phase | 2 |
| Link | NCT03563599 |
| Status | Completed |
| Result | Telacebec (Q203), a New Antituberculosis Agent. |
| Pipline | Telacebec, Q203 |
|---|---|
| Condition/Disease | Buruli Ulcer |
| Phase | 2 |
| Link | NCT06481163 |
| Status | Active, not recruiting |
| Result |
| Pipline | Q301 |
|---|---|
| Condition/Disease | Atopic Dermatitis |
| Phase | 2 |
| Link | NCT02426359 |
| Status | Completed |
| Result | Poster: 2019 AAD annual meeting. |
| Pipline | Q301 |
|---|---|
| Condition/Disease | Atopic Dermatitis |
| Phase | 2 |
| Link | NCT03571620 |
| Status | Completed |
| Result |
For more information about clinical trials:
Phone: +82-31-8060-1600, Monday-Friday, 9am - 6pm (KST)
Email:clinicaltrial_info@qurient.com
Web: www.clinicaltrials.gov